X0508 4 2025-11-18 0 0001711754 Inmune Bio, Inc. INMB 0001767037 Lowdell Mark William C/O INMUNE BIO INC. 225 NE MIZNER BLVD., SUITE 640 BOCA RATON FL 33432 0 1 0 0 Chief Scientific Officer 0 Stock Option (right to buy) 7.80 2025-11-18 4 D 0 400000 D 2028-01-01 Common Stock 400000 0 D Stock Option (right to buy) 1.50 2025-11-18 4 A 0 400000 A 2028-01-01 Common Stock 400000 400000 D Stock Option (right to buy) 3.91 2025-11-18 4 D 0 180000 D 2029-11-24 Common Stock 180000 0 D Stock Option (right to buy) 1.50 2025-11-18 4 A 0 180000 A 2029-11-24 Common Stock 180000 180000 D Stock Option (right to buy) 7.92 2025-11-18 4 D 0 104000 D 2032-03-20 Common Stock 104000 0 D Stock Option (right to buy) 1.50 2025-11-18 4 A 0 104000 A 2032-03-20 Common Stock 104000 104000 D Stock Option (right to buy) 5.05 2025-11-18 4 D 0 140000 D 2034-12-04 Common Stock 140000 0 D Stock Option (right to buy) 1.50 2025-11-18 4 A 0 140000 A 2034-12-04 Common Stock 140000 140000 D Stock Option (right to buy) 9.92 2025-11-18 4 D 0 100000 D 2034-05-13 Common Stock 100000 0 D Stock Option (right to buy) 1.50 2025-11-18 4 A 0 100000 A 2034-05-13 Common Stock 100000 100000 D Effective as of November 18, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2017 Stock Incentive Plan (the "2017 Plan"), 2019 Stock Incentive Plan (the "2019 Plan"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the "2021 Plan") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. /s/ Mark William Lowdell 2025-11-18